AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12389708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleic Acid Sequence‐Based Amplification (NASBA) assay on whole blood samples
Number of subjects: 10
Study 12389708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleic Acid Sequence‐Based Amplification (NASBA) assay
Number of subjects: 10
Study 12389708 — intervention group
Group type: COMPARATOR
Intervention: Automated blood culturing
Number of subjects: 10
Study 9813870 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Mg supplementation (500 mg Mg-oxide.d-1 for 3 weeks)
Number of subjects: 20
Study 9813870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7710435 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment A (20 mg isosorbide-5-mononitrate, oral)
Number of subjects: 24
Study 7710435 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment B (20 mg isosorbide-5-mononitrate, oral)
Number of subjects: 24
Study 7710435 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment C (20 mg isosorbide-5-mononitrate, intravenous)
Number of subjects: 24
Study 2654019 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-trimoxazole
Number of subjects: 44
Study 2654019 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 44
Study 380578 — intervention group
Group type: EXPERIMENTAL
Intervention: Viloxazine (n = 9)
Number of subjects: 19
Study 380578 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (n = 10)
Number of subjects: 19
Study 380578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 30473139 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 12.5 mg daily
Number of subjects: 129
Study 30473139 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily
Number of subjects: 129
Study 30473139 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily
Number of subjects: 129
Study 27646835 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan 97/103 mg two times daily
Number of subjects: 414
Study 27646835 — intervention group
Group type: COMPARATOR
Intervention: irbesartan 300 mg one time daily
Number of subjects: 414
Study 27646835 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril/valsartan
Number of subjects: 414
Study 25962118 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention (Uphungu Wanga)
Number of subjects: 28
Study 25962118 — intervention group
Group type: COMPARATOR
Intervention: Brief education alone
Number of subjects: 28
Study 23642942 — intervention group
Group type: EXPERIMENTAL
Intervention: Panax notoginseng 4000 mg capsules
Number of subjects: 20
Study 23642942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21942957 — intervention group
Group type: EXPERIMENTAL
Intervention: If channel inhibitor ivabradine (12.1±2.3 mg/day)
Number of subjects: 100
Study 21942957 — intervention group
Group type: COMPARATOR
Intervention: Slow release metoprolol succinate (59.1±4.5 mg/day)
Number of subjects: 100
Study 19420144 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent falls
Number of subjects: 1709
Study 19420144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of falling
Number of subjects: 1709
Study 19420144 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention behaviours
Number of subjects: 1709
Study 16691378 — intervention group
Group type: EXPERIMENTAL
Intervention: DWI with b = 0, 150, 500 s/mm2 images
Number of subjects: 40
Study 15364868 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective antegrade cerebral perfusion (SACP)
Number of subjects: 42
Study 15364868 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic circulatory arrest (HCA)
Number of subjects: 42
Study 11312477 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane
Number of subjects: 65
Study 11312477 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 65
Study 11312477 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 65
Study 9395351 — intervention group
Group type: EXPERIMENTAL
Intervention: cpts530/1009
Number of subjects: 0
Study 9395351 — intervention group
Group type: EXPERIMENTAL
Intervention: cpts248/955
Number of subjects: 0
Study 9395351 — intervention group
Group type: COMPARATOR
Intervention: cpts530/1009 and cpts248/955
Number of subjects: 0
Study 7659806 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological approach (ocitocic conduction and peridural anesthesia)
Number of subjects: 81
Study 7659806 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous evolution
Number of subjects: 81
Study 7659806 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (pharmacological and spontaneous)
Number of subjects: 81
Study 7659806 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management
Number of subjects: 81
Study 3303297 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 52
Study 3303297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 52
Study 3303297 — intervention group
Group type: COMPARATOR
Intervention: NSAID continued
Number of subjects: 52
Study 3303297 — intervention group
Group type: COMPARATOR
Intervention: NSAID withdrawn
Number of subjects: 52
Study 3303297 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up
Number of subjects: 52
Study 31493104 — intervention group
Group type: EXPERIMENTAL
Intervention: INFLATE group using a two-channel TENStem eco basic device with two electrodes for pain control during the biopsy.
Number of subjects: 138
Study 31493104 — intervention group
Group type: COMPARATOR
Intervention: TRUS-PNB group receiving 60 mg lidocaine gel intrarectally and infiltration of a prilocaine and bupivacaine mixture (5 mL of 2% prilocaine + 5 mL of 0.25% bupivacaine).
Number of subjects: 138
Study 27899807 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐portioned Foods Group
Number of subjects: 186
Study 27899807 — intervention group
Group type: COMPARATOR
Intervention: Standard Advice Group
Number of subjects: 186
Study 27899807 — intervention group
Group type: EXPERIMENTAL
Intervention: Portion Selection Group
Number of subjects: 186
Study 25213774 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 811 (180 mg SC)
Number of subjects: 0
Study 25213774 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 811
Number of subjects: 0
Study 25213774 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated free serum IFN‐γ concentration levels
Number of subjects: 0
Study 22715020 — intervention group
Group type: EXPERIMENTAL
Intervention: LigaSure Precise (LP)
Number of subjects: 199
Study 22715020 — intervention group
Group type: COMPARATOR
Intervention: FOCUS Shears (FS)
Number of subjects: 199
Study 21676002 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol mixed with energy drink (AmED)
Number of subjects: 56
Study 21676002 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 56
Study 18830192 — intervention group
Group type: EXPERIMENTAL
Intervention: IV infusion of 2 g of magnesium sulfate
Number of subjects: 22
Study 18830192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 16920438 — intervention group
Group type: EXPERIMENTAL
Intervention: New proximal aortic anastomotic device
Number of subjects: 24
Study 16920438 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 24
Study 14764128 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 40 mg twice daily for 12 weeks
Number of subjects: 458
Study 14764128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 458
Study 11348827 — intervention group
Group type: EXPERIMENTAL
Intervention: Peritoneal dialysis simulator model
Number of subjects: 0
Study 11348827 — intervention group
Group type: COMPARATOR
Intervention: Mannequin simulator model
Number of subjects: 0
Study 9151061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 0
Study 9151061 — intervention group
Group type: EXPERIMENTAL
Intervention: Epsilon-aminocaproic acid
Number of subjects: 0
Study 9151061 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0
Study 9151061 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug regimen specified)
Number of subjects: 0
Study 8423888 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (Br) monotherapy
Number of subjects: 22
Study 8423888 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (LD) monotherapy
Number of subjects: 22
Study 8423888 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Br and LD)
Number of subjects: 22
Study 3434885 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane at a concentration of 1 MAC
Number of subjects: 40
Study 3434885 — intervention group
Group type: COMPARATOR
Intervention: Halothane at a concentration of 1 MAC
Number of subjects: 40
Study 31542993 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroschisis (DVM assessment)
Number of subjects: 23
Study 31542993 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroschisis (amniocyte vacuolization assessment)
Number of subjects: 23
Study 31542993 — intervention group
Group type: COMPARATOR
Intervention: Control group with DVM
Number of subjects: 23
Study 31542993 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal villous morphology
Number of subjects: 23
Study 30527103 — intervention group
Group type: EXPERIMENTAL
Intervention: Less tight control of maternal blood pressure
Number of subjects: 683
Study 30527103 — intervention group
Group type: COMPARATOR
Intervention: Tight control of maternal blood pressure
Number of subjects: 683
Study 26977100 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical approach to sampling size for data validation
Number of subjects: 0
Study 26977100 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical techniques for data validation
Number of subjects: 0
Study 24415114 — intervention group
Group type: EXPERIMENTAL
Intervention: TREATED (n=32)
Number of subjects: 49
Study 24415114 — intervention group
Group type: COMPARATOR
Intervention: NOT TREATED (n=17)
Number of subjects: 49
Study 22428455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained trunk flexion with a load (5, 10, and 15 kg)
Number of subjects: 12
Study 22428455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained trunk flexion with a load (15 kg)
Number of subjects: 12
Study 22428455 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained trunk flexion while holding a load
Number of subjects: 12
Study 22428455 — intervention group
Group type: COMPARATOR
Intervention: Unloaded trunk flexion
Number of subjects: 12
Study 19400981 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (duration: 4 weeks)
Number of subjects: 24
Study 19400981 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients with major depression
Number of subjects: 24
Study 19400981 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant treatment (1-2 weeks)
Number of subjects: 24
Study 18046432 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive strategy targeting SBP <130 mm Hg
Number of subjects: 1111
Study 18046432 — intervention group
Group type: COMPARATOR
Intervention: Conventional strategy targeting SBP <140 mm Hg
Number of subjects: 1111
Study 18046432 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite pool of pre-specified fatal and non-fatal events
Number of subjects: 1111
Study 11777998 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 397
Study 11777998 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 397
Study 9606433 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Number of subjects: 0
Study 7761011 — intervention group
Group type: EXPERIMENTAL
Intervention: Peridural morphine hydrochloride (0.5 mg/kg)
Number of subjects: 44
Study 7761011 — intervention group
Group type: COMPARATOR
Intervention: Sublingual buprenorphine (0.4 mg)
Number of subjects: 44
Study 3051332 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulphate (GAGPS) treatment
Number of subjects: 30
Study 3051332 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 30
Study 31303296 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaching-based implementation of the WHO Safe Childbirth Checklist
Number of subjects: 120
Study 31303296 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 120
Study 28545514 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based BP telemonitor with GSM module and unlimited data plan, app for personal healthcare record access, personalized lifestyle coaching, and proficiency training.
Number of subjects: 0
Study 28545514 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordinated PCP-cardiologist care with data sharing via CareLinker website.
Number of subjects: 0
Study 28545514 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 0
Study 25989216 — intervention group
Group type: EXPERIMENTAL
Intervention: Mangiferin (150 mg/day)
Number of subjects: 97
Study 25989216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 23865902 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture flap fixation
Number of subjects: 161
Study 23865902 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression dressing
Number of subjects: 161
Study 23865902 — intervention group
Group type: EXPERIMENTAL
Intervention: Early drain removal
Number of subjects: 161
Study 23865902 — intervention group
Group type: COMPARATOR
Intervention: Conventional method of closed suction drains
Number of subjects: 161
Study 21304153 — intervention group
Group type: EXPERIMENTAL
Intervention: OPLAC™
Number of subjects: 60
Study 21304153 — intervention group
Group type: COMPARATOR
Intervention: LMA Classic™
Number of subjects: 60
Study 18638711 — intervention group
Group type: COMPARATOR
Intervention: Western medicine therapy (WM) including voltaren extended action tablet, methotrexate, and sulfasalazine
Number of subjects: 396
Study 18638711 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine therapy (CM) including Glucosidorum Tripterygll Totorum tablet and Yishen Juanbi Tablet
Number of subjects: 396
Study 18638711 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine therapy (CM)
Number of subjects: 396
Study 17022792 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment (IT)
Number of subjects: 50
Study 17022792 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST)
Number of subjects: 50
Study 15072604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide monotherapy
Number of subjects: 0
Study 15072604 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide as immediate therapy
Number of subjects: 0
Study 15072604 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (CAB) with bicalutamide
Number of subjects: 0
Study 11109422 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 10 mg
Number of subjects: 31
Study 11109422 — intervention group
Group type: COMPARATOR
Intervention: HCT/amiloride 50 mg/5 mg
Number of subjects: 31
Study 9182081 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg oral flosequinan after 10 days of treatment
Number of subjects: 18
Study 8372849 — intervention group
Group type: EXPERIMENTAL
Intervention: Two screening sonograms
Number of subjects: 15530
Study 8372849 — intervention group
Group type: COMPARATOR
Intervention: Conventional obstetric care
Number of subjects: 15530
Study 31452431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinloc
Number of subjects: 439
Study 31452431 — intervention group
Group type: COMPARATOR
Intervention: Hansson pins
Number of subjects: 439
Study 30419911 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light phototherapy (RLPT), 10 min/time, 2 times/day until the end of radiotherapy
Number of subjects: 60
Study 30419911 — intervention group
Group type: COMPARATOR
Intervention: Routine daily care during radiotherapy treatment (Control)
Number of subjects: 60
Study 30419911 — intervention group
Group type: EXPERIMENTAL
Intervention: Red light phototherapy (RLPT)
Number of subjects: 60
Study 26453951 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) program combining cognitive behavioral therapy with relaxation and dietary strategies; 9 sessions (1 hour each) over 13 weeks
Number of subjects: 81
Study 26453951 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive self-management (CSM) program
Number of subjects: 81
Study 24700351 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Interview (CI)
Number of subjects: 98
Study 24700351 — intervention group
Group type: COMPARATOR
Intervention: Free recall
Number of subjects: 98
Study 21780085 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chloride (20 mM) injections daily from E12 to E15
Number of subjects: 0
Study 21780085 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum chloride (2 mM) injections daily from E12 to E15
Number of subjects: 0
Study 21433319 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostamol Uno (PU) 320 mg/day for 36 months
Number of subjects: 50
Study 21433319 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched controls)
Number of subjects: 50
Study 18959779 — intervention group
Group type: EXPERIMENTAL
Intervention: Eudorlin extra
Number of subjects: 3
Study 18959779 — intervention group
Group type: COMPARATOR
Intervention: Nurofen forte
Number of subjects: 3
Study 18959779 — intervention group
Group type: COMPARATOR
Intervention: Migränin
Number of subjects: 3
Study 17153708 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified endocystectomy
Number of subjects: 60
Study 17153708 — intervention group
Group type: COMPARATOR
Intervention: Closed total pericystectomy
Number of subjects: 60
Study 17153708 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 60
Study 14614416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week activation with soft material
Number of subjects: 51
Study 14614416 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-week activation with hard material
Number of subjects: 51
Study 14614416 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week activation with soft material
Number of subjects: 51
Study 14614416 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week activation with hard material
Number of subjects: 51
Study 11061582 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan (50 mg)
Number of subjects: 16
Study 11061582 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (10 mg)
Number of subjects: 16
Study 11061582 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan (2.5 mg)
Number of subjects: 16
Study 11061582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8807731 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonionic contrast media (NICM) iopamidol 370
Number of subjects: 34
Study 8807731 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionic contrast media (ICM) ioxaglate
Number of subjects: 34
Study 8807731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contrast material)
Number of subjects: 34
Study 1557928 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-component pertussis vaccine (containing pertussis toxoid and filamentous haemagglutinin)
Number of subjects: 0
Study 1557928 — intervention group
Group type: COMPARATOR
Intervention: Monocomponent pertussis toxoid vaccine
Number of subjects: 0
Study 3891278 — intervention group
Group type: EXPERIMENTAL
Intervention: Netilmicin
Number of subjects: 0
Study 3891278 — intervention group
Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 0
Study 30653043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemiarthroplasty
Number of subjects: 219
Study 30653043 — intervention group
Group type: COMPARATOR
Intervention: Screw Fixation
Number of subjects: 219
Study 29968397 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day of baclofen
Number of subjects: 72
Study 29968397 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg baclofen
Number of subjects: 72
Study 29968397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 26050104 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab 0.2 mg/kg weekly with methotrexate
Number of subjects: 70
Study 26050104 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab 0.4 mg/kg weekly with methotrexate
Number of subjects: 70
Study 26050104 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab 0.8 mg/kg weekly with methotrexate
Number of subjects: 70
Study 26050104 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 70
Study 26050104 — intervention group
Group type: EXPERIMENTAL
Intervention: Itolizumab with methotrexate
Number of subjects: 70
Study 24737255 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 200 mg
Number of subjects: 207
Study 24737255 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 400 mg
Number of subjects: 207
Study 24737255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study 22218013 — intervention group
Group type: EXPERIMENTAL
Intervention: Consuming breakfast
Number of subjects: 21
Study 22218013 — intervention group
Group type: COMPARATOR
Intervention: Omitting breakfast
Number of subjects: 21
Study 20142538 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination latanoprost-timolol (FCLT)
Number of subjects: 0
Study 20142538 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 0
Study 20142538 — intervention group
Group type: COMPARATOR
Intervention: Timolol
Number of subjects: 0
Study 17356043 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF((low)) group (n = 70)
Number of subjects: 172
Study 17356043 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF((high)) group (n = 68)
Number of subjects: 172
Study 17356043 — intervention group
Group type: COMPARATOR
Intervention: Conventional GH dose of 40 microg/kg/d (n = 34)
Number of subjects: 172
Study 15699378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day administered three times daily (TID)
Number of subjects: 0
Study 15699378 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day administered twice daily (BID)
Number of subjects: 0
Study 15699378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0